Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05933525 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model
A Phase 2 study of Diarrhea and Travelers' Diarrhea, sponsored by Immuron.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05933525 is a Phase 2 study of Diarrhea and Travelers' Diarrhea that has completed, run by Immuron. The registered enrollment target is 60 participants, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05933525, a Phase 2 study of Diarrhea and Travelers' Diarrhea, has completed, sponsored by Immuron.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled study to investigate if Travelan® protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli (ETEC) strain H10407.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Travelan
Study Locations (1)
Maryland
- Pharmaron Clinical Pharmacology Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-05-29 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05933525
The ClinicalTrials.gov registry entry for NCT05933525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 155-participant average among 24 other Diarrhea trials with a reported enrollment target (61% lower). The listed sponsor is Immuron, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diarrhea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05933525 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05933525 about?
NCT05933525 is a clinical study titled "Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model". This is a randomized, double-blind, placebo-controlled study to investigate if Travelan® protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli (ETEC) strain H10407.
What is the current status of trial NCT05933525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-05-29. Estimated completion is 2024-12-30.
What conditions does trial NCT05933525 study?
This clinical trial studies the following conditions: Diarrhea, Travelers' Diarrhea, Infectious Diarrhea.
What interventions are being tested in trial NCT05933525?
The interventions under investigation include: Placebo (OTHER), Travelan (BIOLOGICAL).
Who is sponsoring clinical trial NCT05933525?
This trial is sponsored by Immuron, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05933525 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fecal Microbiota Transplantation for IBS
RECRUITING · Phase 2
-
MTT for Children With ASD Who Have Gastrointestinal Disorders
ACTIVE NOT RECRUITING · Phase 2
-
Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Colesevelam for Lenalidomide-Associated Diarrhea
COMPLETED · Phase 2
-
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
COMPLETED · Phase 2
-
ETEC Logistics Trial (TREK)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.